Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System.

Moure R, Domingo P, Villarroya J, Gasa L, Gallego-Escuredo JM, Quesada-López T, Morón-Ros S, Maroto AF, Mateo GM, Domingo JC, Villarroya F, Giralt M.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00029-18. doi: 10.1128/AAC.00029-18. Print 2018 Jun.

2.

Novel inhibitors of Staphylococcus aureus RnpA that synergize with mupirocin.

Lounsbury N, Eidem T, Colquhoun J, Mateo G, Abou-Gharbia M, Dunman PM, Childers WE.

Bioorg Med Chem Lett. 2018 Apr 1;28(6):1127-1131. doi: 10.1016/j.bmcl.2018.01.022. Epub 2018 Jan 31.

PMID:
29463447
3.

Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors.

Al-Ashmawy AAK, Ragab FA, Elokely KM, Anwar MM, Perez-Leal O, Rico MC, Gordon J, Bichenkov E, Mateo G, Kassem EMM, Hegazy GH, Abou-Gharbia M, Childers W.

Bioorg Med Chem Lett. 2017 Jul 15;27(14):3117-3122. doi: 10.1016/j.bmcl.2017.05.044. Epub 2017 May 15.

PMID:
28571824
4.

Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.

Negredo E, Estrada V, Domingo P, Gutiérrez MD, Mateo GM, Puig J, Bonjoch A, Ornelas A, Echeverría P, Estany C, Toro J, Clotet B.

J Antimicrob Chemother. 2017 Mar 1;72(3):844-849. doi: 10.1093/jac/dkw504.

PMID:
27999056
5.

Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.

Crespo M, Navarro J, Martinez-Rebollar M, Podzamczer D, Domingo P, Mallolas J, Saumoy M, Mateo GM, Curran A, Gatell J, Ribera E.

HIV Clin Trials. 2016 May;17(3):89-95. doi: 10.1080/15284336.2016.1149929. Epub 2016 Mar 16.

PMID:
27125363
6.

Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy.

Lounsbury N, Mateo G, Jones B, Papaiahgari S, Thimmulappa RK, Teijaro C, Gordon J, Korzekwa K, Ye M, Allaway G, Abou-Gharbia M, Biswal S, Childers W Jr.

Bioorg Med Chem. 2015 Sep 1;23(17):5352-9. doi: 10.1016/j.bmc.2015.07.056. Epub 2015 Jul 29.

PMID:
26278028
7.

HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma.

Peraire J, López-Dupla M, Alba V, Beltrán-Debón R, Martinez E, Domingo P, Asensi V, Leal M, Viladés C, Inza MI, Escoté X, Arnedo M, Mateo G, Valle-Garay E, Ferrando-Martinez S, Veloso S, Vendrell J, Gatell JM, Vidal F; HIV-1 Lipodystrophy Study Group.

Clin Microbiol Infect. 2015 Jul;21(7):711.e1-8. doi: 10.1016/j.cmi.2015.04.002. Epub 2015 Apr 14.

8.

Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.

Negredo E, Diez-Pérez A, Bonjoch A, Domingo P, Pérez-Álvarez N, Gutierrez M, Mateo G, Puig J, Echeverría P, Escrig R, Clotet B.

J Antimicrob Chemother. 2015 Jul;70(7):2104-7. doi: 10.1093/jac/dkv063. Epub 2015 Mar 13.

PMID:
25769303
9.

Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients.

Echeverría P, Domingo P, Llibre JM, Gutierrez M, Mateo G, Puig J, Bonjoch A, Pérez-Alvarez N, Sirera G, Clotet B, Negredo E.

Biomed Res Int. 2014;2014:823058. doi: 10.1155/2014/823058. Epub 2014 Aug 7.

10.

Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).

Negredo E, Domingo P, Pérez-Álvarez N, Gutiérrez M, Mateo G, Puig J, Escrig R, Echeverría P, Bonjoch A, Clotet B.

J Antimicrob Chemother. 2014 Dec;69(12):3368-71. doi: 10.1093/jac/dku300. Epub 2014 Aug 13.

PMID:
25125679
11.

Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.

Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, Torres F, Mateo GM, Villarroya J, de los Santos I, Domingo JC, Villarroya F, Del Rio L, Estrada V, Giralt M.

PLoS One. 2014 Feb 26;9(2):e89088. doi: 10.1371/journal.pone.0089088. eCollection 2014.

12.

Psychopathology and psychosocial adjustment in patients with HIV-associated lipodystrophy.

Barata A, Malouf J, Gutierrez M, Mateo GM, Sambeat MA, Gich I, Cadafalch J, Wulff J, Domingo P.

Braz J Infect Dis. 2013 Jul-Aug;17(4):444-9. doi: 10.1016/j.bjid.2012.11.011. Epub 2013 Jun 3.

13.

Autocrine stimulation of clear-cell renal carcinoma cell migration in hypoxia via HIF-independent suppression of thrombospondin-1.

Bienes-Martínez R, Ordóñez A, Feijoo-Cuaresma M, Corral-Escariz M, Mateo G, Stenina O, Jiménez B, Calzada MJ.

Sci Rep. 2012;2:788. doi: 10.1038/srep00788. Epub 2012 Nov 9.

14.

Adipogenic/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden.

Vidal F, Domingo P, Villarroya F, Giralt M, López-Dupla M, Gutiérrez M, Gallego-Escuredo JM, Peraire J, Viladés C, Veloso S, Mateo G, Guallar JP, Richart C.

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):131-7.

PMID:
22580565
15.

Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs.

Ceperuelo-Mallafré V, Escoté X, Viladés C, Peraire J, Domingo P, Solano E, Sirvent JJ, Pastor R, Tinahones F, Leal M, Richart C, Vendrell J, Vidal F; HIV-1 Lipodystrophy Study Group, Alba V, Aguilar A, Auguet T, Chacón MR, López-Dupla M, Megia A, Miranda M, Olona M, Saurí A, Vargas M, Velasco I, Veloso S, Fontanet A, Gutiérrez M, Mateo G, Muñoz J, Sambeat MA.

HIV Med. 2012 May;13(5):297-303. doi: 10.1111/j.1468-1293.2011.00976.x. Epub 2012 Jan 19.

16.

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.

Imaz A, Llibre JM, Mora M, Mateo G, Camacho A, Blanco JR, Curran A, Santos JR, Caballero E, Bravo I, Gayá F, Domingo P, Rivero A, Falcó V, Clotet B, Ribera E.

J Antimicrob Chemother. 2011 Feb;66(2):358-62. doi: 10.1093/jac/dkq432. Epub 2010 Dec 14. Erratum in: J Antimicrob Chemother. 2011 Sep;66(9):2194.

PMID:
21172789
17.

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.

Curran A, Gutirerrez M, Deig E, Mateo G, Lopez RM, Imaz A, Crespo M, Ocaña I, Domingo P, Ribera E.

J Antimicrob Chemother. 2010 Oct;65(10):2195-203. doi: 10.1093/jac/dkq295. Epub 2010 Aug 16.

PMID:
20713406
18.

Pharmacogenetics of adverse effects due to antiretroviral drugs.

Vidal F, Gutiérrez F, Gutiérrez M, Olona M, Sánchez V, Mateo G, Peraire J, Viladés C, Veloso S, López-Dupla M, Domingo P.

AIDS Rev. 2010 Jan-Mar;12(1):15-30. Review.

PMID:
20216907
19.

Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.

Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, Vídriales MB, López-Berges MC, Miguel JF, Orfao A.

Cytometry B Clin Cytom. 2010 Jul;78(4):239-52. doi: 10.1002/cyto.b.20512. Review.

20.

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

Paiva B, Vidriales MB, Pérez JJ, Mateo G, Montalbán MA, Mateos MV, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF; GEM (Grupo Español de MM) cooperative study group; PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.

Haematologica. 2009 Nov;94(11):1599-602. doi: 10.3324/haematol.2009.009100.

21.

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.

Pérez-Persona E, Mateo G, García-Sanz R, Mateos MV, de Las Heras N, de Coca AG, Hernández JM, Galende J, Martín-Nuñez G, Bárez A, Alonso JM, Martín A, López-Berges C, Orfao A, San Miguel JF, Vidriales MB.

Br J Haematol. 2010 Jan;148(1):110-4. doi: 10.1111/j.1365-2141.2009.07929.x. Epub 2009 Oct 11.

PMID:
19821821
22.

The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.

Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, González Y, Bladé J, Lahuerta JJ, Orfao A, San-Miguel JF; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups.

Blood. 2009 Nov 12;114(20):4369-72. doi: 10.1182/blood-2009-05-221689. Epub 2009 Sep 15.

23.

Agonists and partial antagonists acting on the leptin--leptin receptor interface.

Otvos L Jr, Cassone M, Terrasi M, Cascio S, Mateo GD, Knappe D, Hoffmann R, Cudic P, Wade JD, Surmacz E.

Adv Exp Med Biol. 2009;611:497-8. No abstract available.

PMID:
19400282
24.

Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease.

Perez-Andres M, Almeida J, Martin-Ayuso M, De Las Heras N, Moro MJ, Martin-Nuñez G, Galende J, Cuello R, Abuín I, Moreno I, Domínguez M, Hernandez J, Mateo G, San Miguel JF, Orfao A.

Int J Cancer. 2009 Jan 15;124(2):367-75. doi: 10.1002/ijc.23941.

25.

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de Las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups.

Blood. 2008 Nov 15;112(10):4017-23. doi: 10.1182/blood-2008-05-159624. Epub 2008 Jul 31.

26.

Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study.

Falcó V, Olmo M, del Saz SV, Guelar A, Santos JR, Gutiérrez M, Colomer D, Deig E, Mateo G, Montero M, Pedrol E, Podzamczer D, Domingo P, Llibre JM.

J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):26-31. doi: 10.1097/QAI.0b013e31817bec64.

PMID:
18667930
27.

Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.

Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF; PETHEMA Study Group; GEM Study Group.

J Clin Oncol. 2008 Jun 1;26(16):2737-44. doi: 10.1200/JCO.2007.15.4120. Epub 2008 Apr 28.

PMID:
18443352
28.

Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo.

Noto PB, Abbadessa G, Cassone M, Mateo GD, Agelan A, Wade JD, Szabo D, Kocsis B, Nagy K, Rozgonyi F, Otvos L Jr.

Protein Sci. 2008 Jul;17(7):1249-55. doi: 10.1110/ps.034330.108. Epub 2008 Apr 15.

29.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.

Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.

Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5.

30.

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE; European Myeloma Network.

Haematologica. 2008 Mar;93(3):431-8. doi: 10.3324/haematol.11080. Epub 2008 Feb 11.

31.

Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.

del Mar Gutierrez M, Mateo G, Domingo P.

Expert Opin Pharmacother. 2007 Aug;8(12):1871-84. Review.

PMID:
17696790
32.

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Pérez-Persona E, Vidriales MB, Mateo G, García-Sanz R, Mateos MV, de Coca AG, Galende J, Martín-Nuñez G, Alonso JM, de Las Heras N, Hernández JM, Martín A, López-Berges C, Orfao A, San Miguel JF.

Blood. 2007 Oct 1;110(7):2586-92. Epub 2007 Jun 18.

33.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.

Blood. 2006 Oct 1;108(7):2165-72. Epub 2006 Jun 13.

34.

Conventional diagnostics in multiple myeloma.

San Miguel JF, Gutiérrez NC, Mateo G, Orfao A.

Eur J Cancer. 2006 Jul;42(11):1510-9. Epub 2006 Jun 9. Review.

PMID:
16762540
35.

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A, San Miguel JF.

Cancer Res. 2006 Jun 1;66(11):5781-9.

36.

Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.

Pérez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nuñez G, Galende J, Hernandez J, Mateo G, San Miguel JF, Orfao A; Spanish Network on Multiple Myeloma; Spanish Network of Cancer Research Centers.

Cancer. 2006 Mar 15;106(6):1296-305.

37.

Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.

Sarasquete ME, García-Sanz R, González D, Martínez J, Mateo G, Martínez P, Ribera JM, Hernández JM, Lahuerta JJ, Orfão A, González M, San Miguel JF.

Haematologica. 2005 Oct;90(10):1365-72.

38.

Genetic abnormalities and patterns of antigenic expression in multiple myeloma.

Mateo G, Castellanos M, Rasillo A, Gutiérrez NC, Montalbán MA, Martín ML, Hernández JM, López-Berges MC, Montejano L, Bladé J, Mateos MV, Sureda A, de la Rubia J, Díaz-Mediavilla J, Pandiella A, Lahuerta JJ, Orfao A, San Miguel JF.

Clin Cancer Res. 2005 May 15;11(10):3661-7.

39.

Cell cycle analysis of Waldenstrom's macroglobulinemia.

Ocio EM, Mateo G, Vidriales B, Lopez-Berges MC, Garcia-Sanz R, Hernandez JM, Orfao A, San Miguel JF.

Clin Lymphoma. 2005 Mar;5(4):250-2.

PMID:
15794858
40.

Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma.

Ocio EM, Hernandez JM, Mateo G, Sanchez ML, Gonzalez B, Vidriales B, Gutierrez NC, Orfao A, San Miguel JF.

Clin Lymphoma. 2005 Mar;5(4):241-5.

PMID:
15794856
41.

Immunophenotypic approach to the identification and characterization of clonal plasma cells from patients with monoclonal gammopathies.

Pérez-Andrés M, Santiago M, Almeida J, Mateo G, Porwit-MacDonald A, Bjorklund E, Valet G, Kraan J, Gratama JW, D'Hautcourt JL, Merle-Beral H, Lima M, Montalban MA, San Miguel JF, Orfao I; European Working Group on Clinical Cell Analysis; Spanish Network on Multiple Myeloma.

J Biol Regul Homeost Agents. 2004 Jul-Dec;18(3-4):392-8. No abstract available.

PMID:
15786710
42.

Multifunctional role of Erk5 in multiple myeloma.

Carvajal-Vergara X, Tabera S, Montero JC, Esparís-Ogando A, López-Pérez R, Mateo G, Gutiérrez N, Parmo-Cabañas M, Teixidó J, San Miguel JF, Pandiella A.

Blood. 2005 Jun 1;105(11):4492-9. Epub 2005 Feb 3.

43.

Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.

Pérez-Andrés M, Almeida J, Martín-Ayuso M, Moro MJ, Martín-Nuñez G, Galende J, Borrego D, Rodríguez MJ, Ortega F, Hernandez J, Moreno I, Domínguez M, Mateo G, San Miguel JF, Orfao A; Spanish Network on multiple myeloma (G03/136); Spanish Network of Cancer Research Centers (C03/10).

Leukemia. 2005 Mar;19(3):449-55.

PMID:
15674420
44.

Bortezomib is an efficient agent in plasma cell leukemias.

Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, Schenkein D, Pandiella A, San Miguel JF.

Int J Cancer. 2005 Apr 20;114(4):665-7.

45.

Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.

Hernández JM, García-Sanz R, Golvano E, Bladé J, Fernandez-Calvo J, Trujillo J, Soler JA, Gardella S, Carbonell F, Mateo G, San Miguel JF.

Br J Haematol. 2004 Oct;127(2):159-64.

PMID:
15461621
46.

Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients.

García-Sanz R, González-Fraile MI, Mateo G, Hernández JM, López-Berges MC, de las Heras N, Fernández-Calvo J, Ortega F, Portero JA, Bárez A, Galende J, Orfão A, San Miguel JF.

Int J Cancer. 2004 Dec 10;112(5):884-9.

47.

Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma.

Gutiérrez NC, García JL, Hernández JM, Lumbreras E, Castellanos M, Rasillo A, Mateo G, Hernández JM, Pérez S, Orfao A, San Miguel JF.

Blood. 2004 Nov 1;104(9):2661-6. Epub 2004 Jul 6.

48.

Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.

Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutiérrez N, San Miguel JF.

Br J Haematol. 2003 Dec;123(5):858-68.

PMID:
14632777
49.

Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma.

Mateo G, Corral M, Almeida J, López-Berges C, Nieto mJ, García-Marcos A, Vázquez L, del Cañizo C, Orfao A, San Miguel JF.

Haematologica. 2003 Sep;88(9):1013-21.

50.

Immunophenotypic analysis of Waldenstrom's macroglobulinemia.

San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sánchez-Guijo F, Sánchez ML, Escribano L, Bárez A, Moro MJ, Hernández J, Aguilera C, Cuello R, García-Frade J, López R, Portero J, Orfao A.

Semin Oncol. 2003 Apr;30(2):187-95. Erratum in: Semin Oncol. 2002 Jun;15(2):427.

PMID:
12720134

Supplemental Content

Support Center